Biocept, Inc. BIOC NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

26/100

0/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Biocept, Inc. (BIOC) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 25/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

26/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✗

未來

20/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

健康

50/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

15/100

→ Income

成长

58/100

→ Income

✗

收入

10/100

→ Income

估值概览 — BIOC

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.01

EV/EBITDA0.0

每股数据

EPS (TTM)$-56.78

每股账面价值$0.00

每股营收$45.76

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2013	$-55,288.50	$134.25K	$-9.23M	-6877.9%
2014	$-96,744.20	$133.42K	$-15.87M	-11892.3%
2015	$-23,282.30	$609.91K	$-16.95M	-2779%
2016	$-17,292.60	$3.22M	$-18.4M	-570.9%
2017	$-7,074.87	$5.07M	$-21.61M	-426.4%
2018	$-2,634.46	$3.25M	$-24.57M	-756%
2019	$-357.41	$5.53M	$-24.61M	-445.2%
2020	$-43.16	$27.46M	$-17.04M	-62.1%
2021	$-5.73	$61.25M	$-2.82M	-4.6%
2022	$-56.78	$25.86M	$-32.09M	-124.1%